Expansion of a low-cost, saliva-based PCR test for the detection of mpox virus

- 3 Russell J Thomas^{1,2*}, Orchid M. Allicock^{1*}, Devyn Yolda-Carr¹, Katherine Fajardo¹, Sydney A. Steel¹,
- 4 Chessley B. Blacklock¹, Theresa Zepeda³, Maurice Brownlee⁴, Shyam Saladi^{2,3}, James Parkin³, Anne
- 5 L. Wyllie^{1,2}

1

6

10

12

16

18

- ¹Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT,
- 8 USA; ²SalivaDirect Inc., New Haven, CT, USA; ³Neelyx Labs, Wood Dale, IL, USA; ⁴Wellness Homes
- 9 of Chicago, Chicago, IL, USA
- 11 *These authors contributed equally to the study
- 13 **Correspondence**:
- 14 Anne Wyllie
- 15 awyllie@gmail.com
- 17 **Word Count:** 3,071 (including references in square brackets)

ABSTRACT

Background. Current recommendations for the diagnosis of mpox rely on lesion-swabs as the gold-standard specimen type, even though many patients experience symptoms prior to lesion-onset. Alternative sample types, such as saliva, which enable earlier detection could bolster the mpox response by mitigating transmission and facilitating access to antiviral treatments.

Methods. We evaluated five PCR assays and compared their detection of mpox DNA extracted from 30 saliva specimens collected in Spectrum SDNA-1000 tubes. We sequenced seven mpox-positive samples and assessed concordance with the primers and probes of the PCR assays. Following, we incorporated these PCR assays into a simplified, extraction-free protocol to evaluate its feasibility for testing raw (unsupplemented) saliva samples. To further explore the potential of this approach, we investigated the stability of mpox detection in raw saliva diluted 1:10 and 1:100 in mpox-negative saliva, after storage at 4°C, room temperature (~19°C), 30°C, and 40°C for 72 hours and through simulated shipping conditions.

Results. Despite identifying three nucleotide substitutions in the CDC's Monkeypox virus Generic Real-Time PCR Test's primer sequences, we observed no difference in the mean Ct-values generated between assays. We successfully incorporated each assay into our salivabased extraction-free PCR protocol. Detection in raw saliva following storage at 4°C, ~19°C, and 30°C remained relatively stable for 24-48 hours and following simulated shipping conditions.

Conclusions. This pilot investigation supports a flexible, saliva-based, extraction-free PCR test as a promising approach for diagnosis, outbreak response or ongoing surveillance of mpox. With detection in raw saliva remaining stable for 24-48 hours and through simulated shipping temperatures, saliva-based sampling and simplified testing could reduce diagnostic costs, increase access to testing and address hurdles in low- and middle-income countries.

Keywords: mpox, saliva, qPCR, molecular diagnostics

BACKGROUND

Countries in Western and Central Africa have long dealt with outbreaks of mpox virus, with a likely rodent reservoir contributing to spillover [1]. Few outbreaks of mpox virus have occurred outside of Africa, and when they have, they have been largely self-limiting. However, in 2022, the virus spread globally, particularly in the sexual networks of men who have sex with men [2]. Much like the challenges seen with SARS-CoV-2, public health systems struggled as case counts rapidly grew, with testing bottlenecks and insufficient access to treatment and prophylaxis [2].

Mpox infection typically presents with a viral prodrome followed by the characteristic "pox" lesions. During the 2022 outbreak, studies highlighted that cases were experiencing oral or mucosal lesions, with some reporting oropharyngeal symptoms first [2,3]. These reports corroborate historical data; a study from the Democratic Republic of Congo found that 29% of cases had mouth/throat lesions, with 78% of cases also reporting a sore throat, with blood and pharyngeal samples confirming infection earlier than lesion swabs [4].

Through 2022, saliva emerged as a viable diagnostic specimen for mpox, demonstrating high sensitivity [5-9]. Notably, Allen-Blitz et al. found that testing saliva accurately identified 22 cases, four of which did not have a rash and one had no symptoms at all [5]. Hernaez et al. found systemic symptoms and lesions associated with higher viral loads in saliva and isolated infectious virus from 22/33 saliva samples [8]. When followed over the course of the infection, mpox has been detected in saliva at lower qPCR cycle threshold (Ct) values than from skin lesions [6,7] and oral swab samples [9]. In a systematic review, saliva, anorectal and skin lesion samples had the highest viral loads, all greater than that of pharyngeal samples [10]. Moreover, viral loads peaked earliest in saliva, within four days of symptom onset [10], with Brosius et al. detecting DNA and replication-competent mpox virus up to four days before symptom onset [11]. While detection of mpox in saliva typically declines within 14 days of symptoms onset [10], mpox virus has been reported in saliva 76 days after diagnosis [12]. The diagnostic implications for this suggest that mpox virus can circulate systemically prior to lesions and in some cases following their resolution, which raises questions surrounding the potential for asymptomatic transmission and opportunities for improved screening measures, particularly of close-contacts.

Together with saliva being a CDC-recognized source of transmission [13], the growing body of literature underscores the potential of saliva as a specimen type for the detection of mpox virus – its advantages including its ease of self-collection and ability to detect infection prior to lesion onset. With these benefits supporting serial sample collection from exposed individuals, this could identify cases earlier than lesion development. Early detection facilitates faster access to antivirals, which may lessen the severity of disease and concomitantly, facilitates earlier isolation, thus aiding public health workers in halting transmission chains. Therefore, in this study, we evaluated the potential of a simplified PCR test for the detection of mpox virus in saliva, aiming to enhance outbreak response and sustainable surveillance efforts.

METHODS

83

84

85

86

87

88

89

90

91

92

93

94

100

- 95 Ethics statement
- 96 This study was conducted with Institutional Review Board approval from Yale Human
- 97 Research Protection Program (Protocol ID. 2000033293), which allowed for the use of
- 98 remnant clinical samples and was considered as non-human subjects research. No personal
- 99 identifiable information was permitted for use in this study.
- 101 Samples
- 102 We received 30 known mpox-positive saliva samples in Spectrum SDNA-1000 collection
- devices from FlowHealth (Culver City, CA). These collection devices contain patented
- preservative media to stabilize analytes. Additionally, we received five raw (unsupplemented)
- mpox-positive saliva samples from Neelyx Labs (Wood Dale, IL) that were collected from
- 106 patients with positive lesion-swabs.
- 108 PCR assay performance
- 109 Using synthetic mpox virus DNA (ATCC VR-3270SD, ATCC Manassas, VA), we assessed the
- limit of detection (LOD) for five different PCR assays: the Logix Smart™ Mpox (2-Gene) RUO
- 111 (Co-Diagnostics, Inc., Salt Lake City, UT), the Mirimus MPOX RT-PCR assay (Mirimus Labs,
- Brooklyn, NY), the assay targeting Clade II developed by Yu Li et al. [14], and the CDC
- assays consisting of targets for both mpox virus and non-variola orthopoxvirus [15] (**Table 1**).
- 114 As the sequences for the primers and probes of the Logix Smart[™] Mpox (2-Gene) RUO
- assay from Co-Diagnostics, Inc. are proprietary, they are not listed. Two target assays had

Triplicate tests were performed using two-fold dilution series of the synthetic DNA controls in water, ranging from 100 copies/µl to 1 copy/µl. Reaction mixes, including primer and probe concentrations, either followed the manufacturer's instructions (Co-Diagnostics), the CDC guidance for the detection of non-variola orthopoxvirus (CDC and Clade II assays) [15], or as detailed in **Supplementary Table 1** (Mirimus). Assays other than the Logix Smart™ Mpox (2-Gene) RUO assay from Co-Diagnostics were run with the Luna® Universal One-Step RT-qPCR Kit (New England Biolabs, MA). Thermocycler conditions for each assay are provided in **Supplementary Table 2**. For the Mirimus MPOX RT-PCR assay, the CDC Monkeypox virus Generic Real-Time PCR Test, and the CDC Non-variola Orthopoxvirus Real-Time PCR Test, samples were considered positive when Ct values <40. For the Logix Smart™ Mpox (2-Gene) RUO assay and the assay targeting Clade II samples were considered positive when Ct values were <42.

We then validated the five PCR assays on the 30 samples received from FlowHealth. In each assay, 5 µl of DNA template, extracted using the MagMAX[™] Viral/Pathogen Nucleic Acid Isolation Kit (ThermoFisher Scientific, MA), was tested in a 20 µl reaction volume.

Table 1. Gene targets, primers, and probe sequences of the mpox PCR assays evaluated

Assay	Supplier	Gene Targets	Component	Sequence
Mpox (2-Gene)	Co-Diagnostics, Inc. Salt Lake City, UT	L6R (T3) F8L (T4)	Forward Primer	Proprietary
			Reverse Primer	Proprietary
			Probe	Proprietary

Mirimus MPOX	Mirimus Labs,	G2R (Generic)	Forward	5'-GGA AAA TGT AAA GAC AAC
RT-PCR Assay	Brooklyn, NY	E9L	Primers	GAA TAC AG-3'
				5'-TCA ACT GAA AAG GCC ATC TAT GA-3'
			Reverse Primers	5'-GCT ATC ACA TAA TCT GGA AGC GTA-3'
				5'-GAG TAT AGA GCA CTA TTT CTA AAT CCC A-3'
			Probes	5'-FAM-AAG CCG TAA TCT A <bhq-1dt>GT TGT CTA TCG TGT CC-Spacer C6-3'</bhq-1dt>
				5'-FAM-CCA TGC AAT A (T-BHQ1) A CGT ACA AGA TAG TAG CCA AC-Phos-3'
Clade II RT-PCR Assay	Yu Li <i>et. Al</i> (11)	G2R (Clade II)	Forward Primer	5'-CAC ACC GTC TCT TCC ACA GA-3'
			Reverse Primer	5'-GAT ACA GGT TAA TTT CCA CAT CG-3'
			Probe	5' FAM-AAC CCG TCG TAA CCA GCA ATA CAT TT-3' BHQ1
CDC Monkeypox virus Generic Real- Time PCR Test	Centers for Disease Control and Prevention, USA	G2R (Generic)	Forward Primer	5'-GGA AAA TGT AAA GAC AAC GAA TAC AG-3'
			Reverse Primer	5'-GCT ATC ACA TAA TCT GGA AGC GTA-3'
			Probe	5'-FAM-AAG CCG TAA TCT A <bhq-1dt>G TTG TCT ATC</bhq-1dt>

				GTG TCC-Spacer C6-3'
CDC Non-variola Orthopoxvirus Generic Real-Time PCR Test	Centers for Disease Control and Prevention, USA	E9L	Forward Primer Reverse Primer Probe	5'-TCA ACT GAA AAG GCC ATC TAT GA-3' 5'-GAG TAT AGA GCA CTA TTT CTA AAT CCC A-3' 5'-FAM-CCA TGC AAT A (T–BHQ1) A CGT ACA AGA TAG TAG CCA AC-Phos-3'

Extraction-free workflows

To explore the potential of streamlined, extraction-free PCR testing of saliva for the detection of mpox virus, we validated each of the three SalivaDirect workflows developed for the detection of SARS-CoV-2 [16] on three raw saliva samples from Neelyx Labs. Briefly, workflow one includes the addition of proteinase K followed by heat inactivation at 95°C for 5 minutes, workflow two includes heat treatment at 95°C without addition of proteinase K, and workflow three includes heat pre-treatment at 95°C for 30 minutes, followed by addition of proteinase K, then heat inactivation at 95°C for 5 minutes.

Stability of detection of mpox virus in raw, unsupplemented saliva

Having demonstrated the stability of detection of other respiratory pathogens in raw saliva [17–19], we explored the stability of the detection of mpox virus DNA in the raw mpox-positive samples diluted 1:10 and 1:100 into mpox-negative saliva. Saliva lysates prepared from the 1:10 dilutions using workflow one of the extraction-free protocol were tested with the Logix Smart™ Mpox (2-Gene) RUO assay and the lysates prepared from the 1:100 dilutions were tested with the Mirimus MPOX RT-PCR assay. Time zero values were adjusted based on this dilution factor, for which a dilution of 1:10 would yield approximately a +3 increase in Ct value. To test stability, we assessed the change in Ct values at 24, 48, and 72 hours of incubation at 4°C, room temperature (~19°C), 30°C, and 40°C. Due to limited volume of raw saliva, we further assessed the stability of detection using the DNA extracted from a subset of the saliva samples in Spectrum SDNA-1000 collection devices, spiked into raw mpox-negative saliva at a ratio of 1:100, and incubated at room temperature for up to 72 hours.

Additionally, we assessed the stability of mpox detection following incubation through a modification of the US FDA's summer and winter shipping profile conditions, modeled after International Safe Transit Association (ISTA) 7D shipping standards. Due to limited sample volume, only three samples were run through the simulated shipping profiles, and all three samples were diluted 1:5 into mpox-negative saliva.

Amplicon sequencing from saliva samples

To assess concordance of the primers and probes of the assays, we followed the sequencing protocol developed by Chen *et. al.* [20], after performing DNA extraction on the 30 known-positive samples collected into Spectrum SDNA-1000 tubes using the MagMAX[™] Viral/Pathogen Nucleic Acid Isolation Kit (ThermoFisher Scientific, MA). After selecting specimens with Ct values <31 following PCR testing using the Logix Smart[™] Mpox (2-Gene) RUO assay, we proceeded with sequencing seven saliva specimens using the Yale Center for Genomic Analysis' Illumina MiSeq at a depth of 1.5 million reads, then followed the bioinformatics pipeline detailed by Chen *et al.* [20].

Next, we performed a reference-guided whole genome alignment using a reference sequence retrieved from the National Center for Biotechnology Information's (NCBI) GenBank. We compared the nucleotide sequences of the primers and probes of the assays used in this study against the aligned sequences for concordance using Geneious Prime® v2023.1.1. We retrieved an additional 1,560 complete genomes from GenBank with collection dates from January 1st, 2022 through April 7th, 2023. The primers and probes of the assays were then compared across the new alignment which included a total of 1,484 sequences after sequence quality checks. Lineages were assigned using Nextcalde [21], according to Happi *et al.* [22].

Statistical methods

Statistical analyses were performed using R v4.2.2 (2022-10-31) and data visualizations were produced using GraphPad Prism v9.4.1. We used a logistic regression model to see if there was a difference in detection as well as a one-way ANOVA to determine whether there was a difference in mean Ct values across assays.

To evaluate the impact of temperature over time, a linear model was used. An interaction term was used to evaluate the effect of time and temperature by sample (time*temperature).

The Δ Ct value represents the change in the Ct value from saliva under each condition

(categorical). The reference group for time was zero, and the reference group for temperature

was room temperature (~19°C). Samples where no mpox virus DNA was detected were set to

Ct = 45.00. P values of less than 0.05 were considered significant.

RESULTS

198

199

200

201

202

203

204

212

- 205 PCR assay performance
- 206 The limit of detection (LOD), determined using the synthetic mpox virus DNA (ATCC VR-
- 207 3270SD) was 3 copies/µl for the Mirimus MPOX RT-PCR assay and 1 copy/µl for both CDC
- 208 assays. The Logix Smart™ Mpox (2-Gene) RUO assay did not detect the synthetic DNA used
- so the LOD could not be determined. When testing DNA extracted from saliva collected in
- 210 Spectrum SDNA-1000 collection devices, all assays performed comparably at detection
- 211 (p>0.05). Mean Ct values generated did not differ across the assays (p=0.59).
- 213 Extraction-free workflows for testing saliva for the detection of mpox virus
- 214 Detection of mpox virus in saliva was comparable across all three extraction-free workflows
- 215 (Supplementary Figure 1). Due to limited sample size, it was not possible to statistically
- 216 quantify the differences in performance of the workflows.
- 218 Stability of detection of mpox virus in saliva
- 219 The detection of mpox virus remained relatively stable in raw saliva for 24-48 hours, with
- degradation notable at 72 hours (Figure 1). As compared to time zero, we observed an
- increase of 2.14 Ct, 2.55 Ct, and 4.72 Ct, at 24, 48, and 72 hours, respectively for Co-
- Diagnostic's T3 target and an increase of 2.70 Ct, 3.05 Ct, and 4.99 Ct, respectively for the
- 223 T4 target. When fitting the linear model with the interaction term, we found that at 40°C,
- temperature makes degradation worse over time. We observed similar results for the samples
- 225 that were diluted 1:100 in negative saliva and tested with the Mirimus MPOX RT-PCR assay
- 226 (see **Supplementary Figure 2**). When testing the stability of detection of naked mpox DNA
- 227 spiked directly into raw saliva at room temperature, as compared to time zero, we observed a
- mean increase of <2 Ct at 24 hours and 4.2 Ct at 72 hours (see **Supplementary Table 4** for

229 data).




Figure 1. Stability of mpox virus detection in raw (unsupplemented) saliva after prolonged storage at different temperatures. Mpox-positive saliva samples were diluted 1:10 into raw, mpox-negative saliva. Prepared saliva lysates were tested by PCR using the Co-Diagnostics Logix Smart™ Mpox (2-Gene) RUO assay. The "T3" target cycle threshold (Ct) values are shown as solid lines, the "T4" target Ct values are shown as dotted lines. Results suggest that the detection of mpox virus remains relatively stable for approximately 24–48 hours across all storage conditions, with reduced stability in raw saliva at 40°C. While the low viral load in sample 5 resulted in its lack of detection at 24 and 48 hours of incubation at 40°C, the T4 target was detected at 72 hours, likely due to stochastic fluctuations at such low levels.

Detection of mpox virus in raw saliva also remained stable following the 56-hour incubation through temperatures and time periods simulating summer and winter shipping conditions (**Figure 2**), suggesting that saliva samples collected for testing for mpox may be sent through postal systems while maintaining sensitivity.




Figure 2. Detection of mpox virus in raw (unsupplemented) saliva remained stable after cycling through temperatures representing shipping conditions encountered in summer and winter. Three mpox-positive saliva samples were diluted 1:5 into raw mpox-negative saliva and (♠) cycled through simulated summer and winter shipping profiles, recommended by the US Food and Drug Administration for the validation of remote sample collection. Following, saliva lysates were prepared following workflow one then tested by PCR using the Co-Diagnostics Logic Smart™ Mpox (2-Gene) RUO assay, CDC Monkeypox virus Generic Real-Time PCR assay, CDC Non-variola Orthopoxvirus Generic Real-Time PCR assay, and Mirimus MPOX RT-PCR assay. (฿) Resulting cycle threshold (Ct)

Amplicon sequencing from saliva samples

We sequenced whole mpox virus genomes from ten saliva samples according to the amplicon-based sequencing protocol. We were able to sequence over 95% of the genome from seven of the ten samples (see Supplementary Table 3; GenBank Accession Numbers PP977060-PP977067). All of the samples sequenced clustered within clade IIb, falling within lineage B1. Three of the sequences were identified in sub lineages B1.2.1, B.1.4 and B.1.17.

After aligning the seven consensus sequences to the reference genome "NC_063383", we visually examined the alignment of the forward primers, reverse primers, and probes across the different assays. We found two different mismatches with the CDC's Monkeypox virus Generic RT-PCR Assay. The sequences had a single nucleotide substitution in the forward and reverse primers.

Importantly, the reference sequence collected in Nigeria in 2018, only had a mismatch in the forward primer; there were no nucleotide substitutions in the reverse primer or the probe. All primers and probes of the other assays were concordant with the generated sequence as well as the reference sequence. The discordant sequences and the primers/probes can be seen in Table 3. Furthermore, alignment with genomes retrieved from Genbank, confirmed that indeed the primers for the CDC's Monkeypox virus Generic Real-Time PCR Test had several mismatches across the 1,484 genomes. Neither the Clade IIa Assay nor the CDC's Nonvariola Orthopoxvirus Generic Real-Time PCR Test primer and probe sets were affected.

These findings mostly agree with the results reported by Wu *et al.* [23]. In our study, 100% of the 1,484 sequences had the A6G substitution in the forward primer, while 99.5% (n=1,476) sequences included in our alignment had the G17A substitution in the reverse primer. Additionally, we observed 3 sequences with a G16A substitution in the reverse primer – all of which were from the United States.

Table 3. CDC Monkeypox virus Generic Real-Time PCR Test primer concordance with 1,483 sequences aligned to reference sequence 'NC_063383'

Nucleotide Type	Nucleotide Sequence	Number Observed
Mpox Sequence	5'-GGA AA G TGT AAA GAC AAC GAA TAC AG-3'	1,484 (100%)
Forward Primer	5'-GGA AAA TGT AAA GAC AAC GAA TAC AG-3'	
Mpox Sequence	5'-GCT ATC ACA TAA TCT G A A AGC GTA-3'	1,476 (99.5%)
Reverse Primer	5'-GCT ATC ACA TAA TCT G G A AGC GTA-3'	1,110 (00.070)
Mpox Sequence	5'-GCT ATC ACA TAA TCT A AA AGC GTA-3'	3 (0.2%)
Reverse Primer	5'-GCT ATC ACA TAA TCT G GA AGC GTA-3'	

^{*}Nucleotides underlined and bolded represent substitutions in the mpox sequence pulled from NCBI's Nucleotide database and the corresponding mismatch in the PCR primer.

DISCUSSION

Numerous studies since the 2022 outbreak of mpox have investigated the detection of mpox virus in saliva [5–9,12,24], reporting its high concordance with lesion swabs [8,24] and higher viral load (as approximated by Ct values) in saliva in comparison to other respiratory samples [9], and sometimes also lesion swabs [6,7]. With a geographically diverse network of clinical laboratories connected through the SalivaDirect FDA Emergency Use Authorization PCR test [25], we recognized its potential to greatly bolster the response to the US mpox outbreak. Leveraging previously published and commercially available assays to support the rapid adaptation of our streamlined PCR test for SARS-CoV-2 [26], we confirmed the comparable performance of five different PCR assays and incorporated them into our extraction-free protocol. Extraction-free workflows further reduce costs by minimizing laboratory overhead for sample processing, requiring less equipment and reagents, while facilitating timely results [9,26–28]. In countries where supply-chain infrastructure for test kit materials, reagents, and laboratory equipment may be strained, having a flexible platform may reduce barriers to testing while offering flexibility for fitting into existing laboratory regulations and/or processes.

To further support access to testing, we considered it essential to evaluate the stability of mpox detection in raw (unsupplemented) saliva to facilitate cold-chain-free options for both low-cost and remote and/or discrete sample collection, which holds potential as a means for frequent, follow-up testing in exposed individuals, before the appearance of lesions. Expanding upon the findings of Yinda *et al.*, demonstrating stability of mpox virus spiked into saliva over the course of 20 days [29], our study demonstrates the stable detection of mpox virus DNA in raw saliva for 24-48 hours and under simulated seasonal shipping conditions. This suggests that, similar to recommendations made for variola virus in 1957 [30], samples transported in this window may not require stabilizing media, minimizing test-kit costs as only a collection tube is necessary; cold-chain transport of specimens is only necessary in settings where temperatures near 40°C. It is important to note that as the samples were diluted into mpox-negative saliva, the composition of the pooled negative saliva may have disrupted the integrity of the original sample, thereby negatively-impacting the stability of mpox virus DNA. Despite this, these findings support a possible low-cost solution for at-home sample collection which can provide a more discrete option for groups facing stigma.

Genomic sequencing of pathogens contributes to the understanding and monitoring of outbreaks and transmission chains. The ability to sequence from saliva further negates the requirement of swab-based samples which are typically considered necessary for this. Importantly, the multiple substitutions that we observed in the primers of the CDC's assay highlight the ongoing need for routine genomic surveillance of emerging pathogens to ensure adequate diagnostic performance in the face of virus evolution. The mismatches identified by us and different mismatches reported by others [23,31] reaffirms the necessity of multiplexed assays and mpox-specific targets for reliable diagnosis.

We recognize that the small sample size remains a limitation of our preliminary investigation and that it emphasizes the need for prospective collection of multiple sample types during outbreaks of emerging pathogens to identify best diagnostic practices. While ≤5 clinical samples have been tested in this work, diluting these in negative saliva increased the number

of contrived samples that we could validate across potential storage conditions and across different workflows and PCR assays. Consistent results across these settings is promising and as such, despite these limitations, the results of this study contribute to the expanding body of evidence that supports both extraction-free [9,27] and saliva-based methods for the detection of mpox virus.

Saliva is increasingly being accepted as a clinical sample type across the globe [32,33] and should be considered as a potential tool to aid in the ongoing global need for the timely diagnosis and surveillance of pathogens such as mpox virus. Our open-source PCR test demonstrates how low-cost options could be utilized to support this, particularly when implemented within a testing framework that can support a rapid and flexible outbreak response. However, further research is needed to assess the temporal dynamics of mpox virus in saliva, which will elucidate the window at which we can expect patients to become positive and/or infectious through saliva. As such, questions pertaining to asymptomatic transmission/prolonged viral shedding also remain and identifying these cases is important for halting ongoing human-to-human transmission. Combined, this understanding can aid us in prediction of when disease may be at its worst based on viral load. Therefore, we echo Coppens et al. for studies that prospectively screen close-contacts of confirmed cases to answer these questions [24]. The ongoing need for diagnostics development and sustainable surveillance methods is accentuated by case reports of reinfection, break-through infection following vaccination, and infection of those who have both prior infection and full vaccination [34-36].

ACKNOWLEDGEMENTS

We thank the Grubaugh Laboratory at the Yale School of Public Health for providing guidance on the amplicon-sequencing protocol they developed – in particular Dr. Nathan D. Grubaugh, Nicholas F.G. Chen, and Dr. Chrispin Chaguza. We also would like to thank Mirimus Labs, Co-Diagnostics Inc., and Dr. Delphine Dean at Clemson University for providing us with the PCR assays used in this study. Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health under

Gay Studies for financially supporting this research.

ROLE OF THE FUNDER

- 371 This work was supported by Yale University's Fund for Lesbian and Gay Studies (FLAGS)
- and SalivaDirect, Inc..

368

369

370

373

374

380

381

387

388

389

390 391

392

AUTHOR'S CONTRIBUTIONS.

- 375 ALW conceived and designed the study. OMA, DY-C and ALW managed the study. TZ, MB,
- 376 SS and JP managed sample collection. RJT, OMA, DY-C and KF were responsible for and
- performed the assays. RJT, OMA and ALW performed the analyses and interpreted the data.
- 378 RJT, CB, SAS, OMA and ALW drafted the manuscript. All authors amended and commented
- on the final manuscript.

DISCLOSURES

- 382 ALW has received consulting and/or advisory board fees from Pfizer, Merck, Diasorin, PPS
- Health, Primary Health, Co-Diagnostics, and Global Diagnostic Systems for work unrelated to
- this project, and is Principal Investigator on research grants from Pfizer, Merck, and NIH
- RADx UP to Yale University and from NIH RADx, Balvi.io and Shield T3 to SalivaDirect, Inc..
- 386 All other co-authors declare no potential conflict of interest.

REFERENCES

- [1] R. Pebody, Human Monkeypox in Kasai Oriental, Democratic Republic of Congo, February 1996 October 1997: preliminary report, Weekly Releases (1997–2007) 1 (1997) 1015.
- 393 [2] Thornhill John P., Barkati Sapha, Walmsley Sharon, Rockstroh Juergen, Antinori Andrea, Harrison Luke B., Palich Romain, Nori Achyuta, Reeves Iain, Habibi Maximillian S., Apea 394 395 Vanessa, Boesecke Christoph, Vandekerckhove Linos, Yakubovsky Michal, Sendagorta Elena, Blanco Jose L., Florence Eric, Moschese Davide, Maltez Fernando M., Goorhuis 396 397 Abraham, Pourcher Valerie, Migaud Pascal, Noe Sebastian, Pintado Claire, Maggi Fabrizio, Hansen Ann-Brit E., Hoffmann Christian, Lezama Jezer I., Mussini Cristina, 398 399 Cattelan AnnaMaria, Makofane Keletso, Tan Darrell, Nozza Silvia, Nemeth Johannes, 400 Klein Marina B., Orkin Chloe M., Monkeypox Virus Infection in Humans across 16 401 Countries — April–June 2022, N. Engl. J. Med. 387 (2022) 679–691.
- 402 [3] N. Girometti, R. Byrne, M. Bracchi, J. Heskin, A. McOwan, V. Tittle, K. Gedela, C. Scott,

- S. Patel, J. Gohil, D. Nugent, T. Suchak, M. Dickinson, M. Feeney, B. Mora-Peris, K. Stegmann, K. Plaha, G. Davies, L.S.P. Moore, N. Mughal, D. Asboe, M. Boffito, R. Jones, G. Whitlock, Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis, Lancet Infect. Dis. 22 (2022) 1321–1328.
- [4] P.R. Pittman, J.W. Martin, P.M. Kingebeni, J.-J.M. Tamfum, G. Mwema, Q. Wan, P.
 Ewala, J. Alonga, G. Bilulu, M.G. Reynolds, X. Quinn, S. Norris, M.B. Townsend, P.S.
 Satheshkumar, J. Wadding, B. Soltis, A. Honko, F.B. Güereña, L. Korman, K. Patterson,
 D.A. Schwartz, J.W. Huggins, Kole Human Mpox Infection Study Group, Clinical
 characterization and placental pathology of mpox infection in hospitalized patients in the
 Democratic Republic of the Congo, PLoS Negl. Trop. Dis. 17 (2023) e0010384.
- L.-T. Allan-Blitz, K. Carragher, A. Sukhija-Cohen, P. Ritchie, H. Scott, H. Li, J.D. Klausner, Laboratory validation and clinical performance of a saliva-based test for monkeypox virus, J. Med. Virol. 95 (2023) e28191.
- 417 [6] A. Peiró-Mestres, I. Fuertes, D. Camprubí-Ferrer, M.Á. Marcos, A. Vilella, M. Navarro, L. Rodriguez-Elena, J. Riera, A. Català, M.J. Martínez, J.L. Blanco, Hospital Clinic de Barcelona Monkeypox Study Group, Frequent detection of monkeypox virus DNA in saliva, semen, and other clinical samples from 12 patients, Barcelona, Spain, May to June 2022, Euro Surveill. 27 (2022). https://doi.org/10.2807/1560-7917.ES.2022.27.28.2200503.
- 423 [7] A. Antinori, V. Mazzotta, S. Vita, F. Carletti, D. Tacconi, L.E. Lapini, A. D'Abramo, S.
 424 Cicalini, D. Lapa, S. Pittalis, V. Puro, M. Rivano Capparuccia, E. Giombini, C.E.M.
 425 Gruber, A.R. Garbuglia, A. Marani, F. Vairo, E. Girardi, F. Vaia, E. Nicastri, INMI
 426 Monkeypox Group, Epidemiological, clinical and virological characteristics of four cases
 427 of monkeypox support transmission through sexual contact, Italy, May 2022, Euro
 428 Surveill. 27 (2022). https://doi.org/10.2807/1560-7917.ES.2022.27.22.2200421.
- 429 [8] B. Hernaez, A. Muñoz-Gómez, A. Sanchiz, E. Orviz, A. Valls-Carbo, I. Sagastagoitia, O. Ayerdi, R. Martín, T. Puerta, M. Vera, N. Cabello, J. Vergas, C. Prieto, M. Pardo-Figuerez, A. Negredo, J.M. Lagarón, J. Del Romero, V. Estrada, A. Alcamí, Monitoring monkeypox virus in saliva and air samples in Spain: a cross-sectional study, Lancet Microbe 4 (2023) e21–e28.

436

437

438 439

440

441

442443

444

- [9] Y. Wang, H. Chen, K. Lin, Y. Han, Z. Gu, H. Wei, K. Mu, D. Wang, L. Liu, R. Jin, R. Song, Z. Rong, S. Wang, Ultrasensitive single-step CRISPR detection of monkeypox virus in minutes with a vest-pocket diagnostic device, Nat. Commun. 15 (2024) 3279.
- [10] H. Kim, R. Kwon, H. Lee, S.W. Lee, M. Rahmati, A. Koyanagi, L. Smith, M.S. Kim, G.F. López Sánchez, D. Elena, S.G. Yeo, J.I. Shin, W. Cho, D.K. Yon, Viral load dynamics and shedding kinetics of mpox infection: a systematic review and meta-analysis, J. Travel Med. 30 (2023). https://doi.org/10.1093/jtm/taad111.
- [11] I. Brosius, C. Van Dijck, J. Coppens, L. Vandenhove, E. Bangwen, F. Vanroye, J. Verschueren, ITM MPOX Study Group, S. Zange, J. Bugert, J. Michiels, E. Bottieau, P. Soentjens, J. van Griensven, C. Kenyon, K.K. Ariën, M. Van Esbroeck, K. Vercauteren, L. Liesenborghs, Presymptomatic viral shedding in high-risk mpox contacts: A prospective cohort study, J. Med. Virol. 95 (2023) e28769.
- [12] A. Pettke, F. Filén, K. Widgren, A. Jacks, H. Glans, S. Andreasson, S. Muradrasoli, S.
 Helgesson, E. Hauzenberger, M.L. Karlberg, N. Walai, A. Bjerkner, H. Gourlé, S.
 Gredmark-Russ, O.K. Lindsjö, K. Sondén, H. Asgeirsson, Ten-Week Follow-Up of
 Monkeypox Case-Patient, Sweden, 2022, Emerg. Infect. Dis. 28 (2022) 2074–2077.
- [13] CDC Monkeypox Response: Transmission, CDC (2022).
 https://www.cdc.gov/media/releases/2022/0509-monkeypox-transmission.html (accessed)

452 July 24, 2024).

456

457 458

463 464

465

466 467

- [14] Y. Li, H. Zhao, K. Wilkins, C. Hughes, I.K. Damon, Real-time PCR assays for the specific detection of monkeypox virus West African and Congo Basin strain DNA, J. Virol.
 Methods 169 (2010) 223–227.
 - [15] CDC, PCR Test Procedures, Centers for Disease Control and Prevention (2023). https://www.cdc.gov/poxvirus/mpox/collections/pages/pcr-test-procedures.html (accessed July 24, 2024).
- [16] O.M. Allicock, D. Yolda-Carr, R. Earnest, M.I. Breban, N. Vega, I.M. Ott, C. Kalinich, T.
 Alpert, M.E. Petrone, A.L. Wyllie, Method versatility in RNA extraction-free PCR detection of SARS-CoV-2 in saliva samples, bioRxiv (2021).
 https://doi.org/10.1101/2021.12.27.21268334.
 - [17] I.M. Ott, M.S. Strine, A.E. Watkins, M. Boot, C.C. Kalinich, C.A. Harden, C.B.F. Vogels, A. Casanovas-Massana, A.J. Moore, M.C. Muenker, M. Nakahata, M. Tokuyama, A. Nelson, J. Fournier, S. Bermejo, M. Campbell, R. Datta, C.S. Dela Cruz, S.F. Farhadian, A.I. Ko, A. Iwasaki, N.D. Grubaugh, C.B. Wilen, A.L. Wyllie, Yale IMPACT Research team3, Stability of SARS-CoV-2 RNA in Nonsupplemented Saliva, Emerg. Infect. Dis. 27 (2021) 1146–1150.
- [18] O.M. Allicock, T.-Y. Lin, K.T. Fajardo, D. Yolda-Carr, M. Hislop, D. Zuniga, W. Platt, B. Tuhoy, J. Wang, A.L. Wyllie, Exploring the potential of a saliva-based, RNA-extraction-free PCR test for the multiplexed detection of key respiratory pathogens, bioRxiv (2023). https://doi.org/10.1101/2023.10.04.23296240.
- [19] O.M. Allicock, A. York, P. Waghela, D. Yolda-Carr, D.M. Weinberger, A.L. Wyllie, Impact of Temporary Storage Conditions on the Viability of Streptococcus pneumoniae in Saliva, mSphere 7 (2022) e0033122.
- [20] N.F.G. Chen, C. Chaguza, L. Gagne, M. Doucette, S. Smole, E. Buzby, J. Hall, S. Ash, 476 R. Harrington, S. Cofsky, S. Clancy, C.J. Kapsak, J. Sevinsky, K. Libuit, D.J. Park, P. 477 Hemarajata, J.M. Garrigues, N.M. Green, S. Sierra-Patev, K. Carpenter-Azevedo, R.C. 478 Huard, C. Pearson, K. Incekara, C. Nishimura, J.P. Huang, E. Gagnon, E. Reever, J. 479 480 Razeq, A. Muyombwe, V. Borges, R. Ferreira, D. Sobral, S. Duarte, D. Santos, L. Vieira, J.P. Gomes, C. Aguino, I.M. Savino, K. Felton, M. Baiwa, N. Hayward, H. Miller, A. 481 482 Naumann, R. Allman, N. Greer, A. Fall, H.H. Mostafa, M.P. McHugh, D.M. Maloney, R. Dewar, J. Kenicer, A. Parker, K. Mathers, J. Wild, S. Cotton, K.E. Templeton, G. 483 484 Churchwell, P.A. Lee, M. Pedrosa, B. McGruder, S. Schmedes, M.R. Plumb, X. Wang, R.B. Barcellos, F.M.S. Godinho, R.S. Salvato, A. Ceniseros, M.I. Breban, N.D. 485 486 Grubaugh, G.R. Gallagher, C.B.F. Vogels, Development of an amplicon-based sequencing approach in response to the global emergence of mpox, PLoS Biol. 21 487 488 (2023) e3002151.
- [21] İ. Aksamentov, C. Roemer, E. Hodcroft, R. Neher, Nextclade: clade assignment, mutation calling and quality control for viral genomes, J. Open Source Softw. 6 (2021) 3773.
- [22] C. Happi, I. Adetifa, P. Mbala, R. Njouom, E. Nakoune, A. Happi, N. Ndodo, O. Ayansola,
 G. Mboowa, T. Bedford, R.A. Neher, C. Roemer, E. Hodcroft, H. Tegally, Á. O'Toole, A.
 Rambaut, O. Pybus, M.U.G. Kraemer, E. Wilkinson, J. Isidro, V. Borges, M. Pinto, J.P.
 Gomes, L. Freitas, P.C. Resende, R.T.C. Lee, S. Maurer-Stroh, C. Baxter, R. Lessells,
 A.E. Ogwell, Y. Kebede, S.K. Tessema, T. de Oliveira, Urgent need for a non-discriminatory and non-stigmatizing nomenclature for monkeypox virus, PLoS Biol. 20
 (2022) e3001769.
- 499 [23] F. Wu, J. Oghuan, A. Gitter, K.D. Mena, E.L. Brown, Wide mismatches in the sequences 500 of primers and probes for monkeypox virus diagnostic assays, J. Med. Virol. 95 (2023)

e28395.

- [24] J. Coppens, F. Vanroye, I. Brosius, L. Liesenborghs, S. van Henten, T. Vanbaelen, S. Bracke, N. Berens-Riha, I. De Baetselier, C. Kenyon, P. Soentjens, E. Florence, J. Van Griensven, K.K. Ariën, B.K.M. Jacobs, D. Van den Bossche, M. Van Esbroeck, K. Vercauteren, ITM MPX study group, Alternative sampling specimens for the molecular detection of mpox (formerly monkeypox) virus, J. Clin. Virol. 159 (2023) 105372.
- [25] SalivaDirect EUA Summary, (n.d.). https://www.fda.gov/media/141192/ (accessed February 21, 2021).
- [26] C.B.F. Vogels, A.E. Watkins, C.A. Harden, D.E. Brackney, J. Shafer, J. Wang, C. Caraballo, C.C. Kalinich, I.M. Ott, J.R. Fauver, E. Kudo, P. Lu, A. Venkataraman, M. Tokuyama, A.J. Moore, M.C. Muenker, A. Casanovas-Massana, J. Fournier, S. Bermejo, M. Campbell, R. Datta, A. Nelson, K. Anastasio, M.H. Askenase, M. Batsu, S. Bickerton, K. Brower, M.L. Bucklin, S. Cahill, Y. Cao, E. Courchaine, G. Deluliis, R. Earnest, B. Geng, B. Goldman-Israelow, R. Handoko, W. Khoury-Hanold, D. Kim, L. Knaggs, M. Kuang, S. Lapidus, J. Lim, M. Linehan, A. Lu-Culligan, A. Martin, I. Matos, D. McDonald, M. Minasyan, M. Nakahata, N. Naushad, J. Nouws, A. Obaid, C. Odio, J.E. Oh, S. Omer, A. Park, H.-J. Park, X. Peng, M. Petrone, S. Prophet, T. Rice, K.-A. Rose, L. Sewanan, L. Sharma, A.C. Shaw, D. Shepard, M. Smolgovsky, N. Sonnert, Y. Strong, C. Todeasa, J. Valdez, S. Velazquez, P. Vijayakumar, E.B. White, Y. Yang, C.S. Dela Cruz, A.I. Ko, A. Iwasaki, H.M. Krumholz, J.D. Matheus, P. Hui, C. Liu, S.F. Farhadian, R. Sikka, A.L. Wyllie, N.D. Grubaugh, SalivaDirect: A Simplified and Flexible Platform to Enhance SARS-CoV-2 Testing Capacity, Med (2020). https://doi.org/10.1016/j.medj.2020.12.010.
- [27] Z. Li, A. Sinha, Y. Zhang, N. Tanner, H.-T. Cheng, P. Premsrirut, C.K.S. Carlow, Extraction-free LAMP assays for generic detection of Old World Orthopoxviruses and specific detection of Mpox virus, Sci. Rep. 13 (2023) 21093.
- [28] C. Peno, T.-Y. Lin, M.S. Hislop, D. Yolda-Carr, K. Farjado, A. York, V.E. Pitzer, D.M. Weinberger, A.K. Bei, O.M. Allicock, A.L. Wyllie, A low-cost culture- and DNA extraction-free method for the molecular detection of pneumococcal carriage in saliva, Microbiol Spectr (2024) e0059124.
- [29] C.K. Yinda, D.H. Morris, R.J. Fischer, S. Gallogly, Z.A. Weishampel, J.R. Port, T. Bushmaker, J.E. Schulz, K. Bibby, N. van Doremalen, J.O. Lloyd-Smith, V.J. Munster, Stability of Monkeypox Virus in Body Fluids and Wastewater, Emerg. Infect. Dis. 29 (2023) 2065–2072.
- [30] F.O. Maccallum, J.R. Mcdonald, Effect of temperatures of up to 45 degrees C on survival of variola virus in human material in relation to laboratory diagnosis, Bull. World Health Organ. 16 (1957) 441–443.
- [31] C. for Disease Control, Prevention, Others, Lab alert: MPXV TNF receptor gene deletion may lead to false negative results with some MPXV specific LDTs, (2023).
- [32] E.R. Tobik, L.B. Kitfield-Vernon, R.J. Thomas, S.A. Steel, S.H. Tan, O.M. Allicock, B.L. Choate, S. Akbarzada, A.L. Wyllie, Saliva as a sample type for SARS-CoV-2 detection: implementation successes and opportunities around the globe, Expert Rev. Mol. Diagn. 22 (2022) 519–535.
- [33] S.H. Tan, O.M. Allicock, A. Katamba, C.V.F. Carrington, A.L. Wyllie, M. Armstrong-Hough, Saliva-based methods for SARS-CoV-2 testing in low-and middle-income countries, (2022). https://cdn.who.int/media/docs/default-source/bulletin/online-first/blt.22.288526.pdf?sfvrsn=30da2b19_1 (accessed October 7, 2022).
- [34] S. Accordini, M. Cordioli, E. Pomari, E. Tacconelli, C. Castilletti, People with asymptomatic or unrecognised infection potentially contribute to monkeypox virus transmission, Lancet Microbe 4 (2023) e209.

550

551

552

553

554

555

[36] S. Musumeci, I. Najjar, E.B.E. Amari, M. Schibler, F. Jacquerioz, S. Yerly, A. Renzoni, A. Calmy, L. Kaiser, A Case of Mpox Reinfection, Clin. Infect. Dis. 77 (2023) 135–137.